Aethlon Medical Inc (NASDAQ:AEMD)
| Market Cap | 2.94M-84.1% |
| Revenue (ttm) | 0 |
| Net Income | -6.94M+44.8% |
| EPS | -11.70+83.1% |
| Shares Out | 526.71K |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 43,588 |
| Open | 5.80 |
| Previous Close | 5.86 |
| Day's Range | 5.58 - 5.84 |
| 52-Week Range | 1.41 - 35.70 |
| Beta | 1.40 |
| Analysts | Hold |
| Price Target | 1.50(-73.12%) |
| Earnings Date | Nov 11, 2026 |
Insiders here have filed 1 Form 4 in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About AEMD
Aethlon Medical, Inc. operates as a medical technology enterprise, dedicated to innovating solutions for the diagnosis and treatment of life-threatening and organ-jeopardizing diseases within the United States. Central to its pipeline is the Aethlon Hemopurifier, a clinical-stage immunotherapeutic device. This device is engineered to clear the human circulatory system of detrimental tumor-derived exosomes and perilous viruses. Notably, this capability extends to targeting the COVID-19 virus, its various strains, and associated exosomes. Furthermore, Aethlon Medical maintains a collaborative partnership with the University of Pittsburgh Medical Center's Hillman Cancer Center, conducting studies pertinent to head and neck cancer. Established in 1999, the company is headquartered in San Diego, California.
$AEMD stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in AEMD holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by AEMD's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
AEMD Estimated quarterly lobbying spending
Source: U.S. Senate LDA
AEMD Revenue by Segment or Geography
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New AEMD patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to AEMD from public contracts
Source: USAspending.gov
AEMD Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from AEMD’s recent data — informational, not investment advice